Table of Contents

company-logo

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals Dividend Announcement

• Clover Biopharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Clover Biopharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Clover Biopharmaceuticals Dividend History

Clover Biopharmaceuticals Dividend Yield

Clover Biopharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Clover Biopharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Clover Biopharmaceuticals Financial Ratios

P/E ratio-0.38
PEG ratio0.01
P/B ratio-0.40
ROE112.96%
Payout ratio0.00%
Current ratio0.78
Quick ratio0.44
Cash Ratio0.22

Clover Biopharmaceuticals Dividend FAQ

Does Clover Biopharmaceuticals stock pay dividends?
Clover Biopharmaceuticals does not currently pay dividends to its shareholders.
Has Clover Biopharmaceuticals ever paid a dividend?
No, Clover Biopharmaceuticals has no a history of paying dividends to its shareholders. Clover Biopharmaceuticals is not known for its dividend payments.
Why doesn't Clover Biopharmaceuticals pay dividends?
There are several potential reasons why Clover Biopharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Clover Biopharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Clover Biopharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Clover Biopharmaceuticals a dividend aristocrat?
Clover Biopharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Clover Biopharmaceuticals a dividend king?
Clover Biopharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Clover Biopharmaceuticals a dividend stock?
No, Clover Biopharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Clover Biopharmaceuticals stocks?
To buy Clover Biopharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Clover Biopharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.